MDS/AML Overlap and Novel Therapies with Dr. Naval Daver

August 6, 2018

Aplastic Anemia
MDS International Foundation

Video

Dr. Naval Daver from MD Anderson Cancer Center talks about the relationship between MDS and AML and discusses new and novel treatments for both diseases.

Dr. Naval Daver from MD Anderson Cancer Center talks about the relationship between MDS and AML and discusses new and novel treatments for both diseases. Topics include an overview of MDS and AML, novel therapies for MDS and AML, and future treatments.

Related Videos

How Gene and Cell Therapy Is Developing in Dermatology

Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.

The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD

Comparing New Therapies for Dystrophic Epidermolysis Bullosa

Reviewing 2023 with FDA Commissioner Robert M. Califf, MD

Dunia Hatabah, MD | Image Credit: HCPLive

Ricky Safer: What Clinicians Need to Know About PSC

Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome

Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease

Mercedes Martinez, MD: Treatment Strategies for Autoimmune Hepatitis

Related Content

FDA Grants Nipocalimab Fast Track Designation for Rare Fetal Disease, with Katie Abouzahr, MD

FDA Grants Nipocalimab Fast Track Designation for Rare Fetal Disease, with Katie Abouzahr, MD

Autoimmune Hepatitis at ACG 2023, with Gina Choi, MD

Autoimmune Hepatitis at ACG 2023, with Gina Choi, MD

October 25th 2023

Bitopertin Meets Primary Phase 2 Endpoint in Erythropoietic Protoporphyria | Image Credit: Matt Brown/Unsplash

Bitopertin Meets Primary Phase 2 Endpoint in Erythropoietic Protoporphyria

Rare Disease Report Podcast: FDA Reviews Combination Therapy for Pompe Disease

Rare Disease Report Podcast: FDA Reviews Combination Therapy for Pompe Disease

October 28th 2022

Amy Paller, MD: What Pz-cel, B-VEC Each Bring to Recessive DEB

Amy Paller, MD: What Pz-cel, B-VEC Each Bring to Recessive DEB

Michael B. Gorin, MD, PhD | Image Credit: UCLA

Michael B. Gorin, MD, PhD: Interim TEASE-3 Trial Data in Stargardt Disease

January 10th 2024

Related Content

FDA Grants Nipocalimab Fast Track Designation for Rare Fetal Disease, with Katie Abouzahr, MD

FDA Grants Nipocalimab Fast Track Designation for Rare Fetal Disease, with Katie Abouzahr, MD

Autoimmune Hepatitis at ACG 2023, with Gina Choi, MD

Autoimmune Hepatitis at ACG 2023, with Gina Choi, MD

October 25th 2023

Bitopertin Meets Primary Phase 2 Endpoint in Erythropoietic Protoporphyria | Image Credit: Matt Brown/Unsplash

Bitopertin Meets Primary Phase 2 Endpoint in Erythropoietic Protoporphyria

Rare Disease Report Podcast: FDA Reviews Combination Therapy for Pompe Disease

Rare Disease Report Podcast: FDA Reviews Combination Therapy for Pompe Disease

October 28th 2022

Amy Paller, MD: What Pz-cel, B-VEC Each Bring to Recessive DEB

Amy Paller, MD: What Pz-cel, B-VEC Each Bring to Recessive DEB

Michael B. Gorin, MD, PhD | Image Credit: UCLA

Michael B. Gorin, MD, PhD: Interim TEASE-3 Trial Data in Stargardt Disease

January 10th 2024

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.